Navigation Links
Bioniche Provides a Corporate Update
Date:6/22/2009

BELLEVILLE, ON, June 22 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its corporate activities.

In April, the Company reported that it was experiencing delays in concluding a partnering transaction related to its Mycobacterial Cell Wall-DNA Complex (MCC), formulated as Urocidin(TM), for the intravesical treatment of non-muscle-invasive bladder cancer. At the same time, the Company reported that the maturity date of its secured revolving credit facility with Valens U.S. (formerly Laurus Master Funds) was extended to June 30, 2009.

At this time, the Company can report that a number of activities have been taking place over the past two months to address its short-term liquidity requirements, and progress is being made on these initiatives. It is not expected that these initiatives will be finalized before June 30, 2009, but Valens U.S. has agreed to have the credit facility return to "on demand" status.

About Bioniche Life Sciences Inc.

Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal has been to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
2. Bioniche Represented at House of Commons Sub-Committee on Food Safety
3. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
4. Bioniche Reports Fiscal 2009 Third Quarter
5. Bioniche Provides a Corporate Update
6. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
7. Bioniche Revolving Credit Facility Maturity Date Amended
8. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
9. Bioniche Warrants Expiration Date to be Extended
10. Bioniche Reports Fiscal 2009 Second Quarter
11. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month by ... gums in Vancouver, BC, may be developing gingivitis, the first stage of gum ... diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy to ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants ... focused on finding product improvements that could reduce the occurrence of unplanned extubations ... need help breathing or to provide medication. Sometimes, patient movement can cause unplanned ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Uniform Advantage ... collection featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA ... and cotton easy care stretch twill. , With trendy looks hitting the medical community, ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... radio program, The Sharon Kleyne Hour Power of Water, Global Climate Change and ... to the world’s water crisis and how it affects the human eyes. ...
Breaking Medicine News(10 mins):
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology: